Objective. The objective is to perform a comprehensive review of the literature up to 2015 on the genetics and precision medicine relevant to otitis media.
G enetics is critical in otitis media (OM) pathogenesis, an infectious disorder involving inflammation of the middle ear. Family and twin studies have proven that the heritability of OM is high. Multiple factors and many genes are involved in the predisposition of OM. The genetic risk factors include the transforming growth factor beta (TGFb) signaling pathway, mucin genes, vascular endothelial growth factor, Toll-like receptors (TLRs), and ERK signaling pathways. These pathways overlap and affect innate/adaptive immunity and inflammatory responses of the middle ear mucosa or normal cellular functions (angiogenesis, hypoxia, lymphangiogenesis, mucociliary transport system, mucin production, and mucous cell metaplasia). Increased understanding of these genes and pathways has led to novel therapeutic strategies for OM. Precision medicine (PM)-the use of specific patient genotypic and phenotypic characteristics to inform individualized therapeutic decisions-has also emerged as a consideration for OM management. Tools in PM include molecular diagnostics by panomic analysis and systems biology to understand the specific causes underpinning a patient's OM pathogenesis.
Method and Search Strategy
Published literature in PubMed was searched since the last symposium. Search terms included OM, recurrent acute OM, chronic OM, chronic OM effusion, acute OM, heritability, genetic, SNP, genes, genetic polymorphism, GWAS, linkage study, genetics, signaling pathways, mucins, transforming growth factor beta, Toll-like receptor, mucosal metaplasia, chinchilla genome, and animal model. The search included all published literature with available English abstracts. No further exclusion or selection criteria were employed.
Discussion

Recent Advances in the Genetics of OM
Chronic infectious diseases, including OM, have been linked to specific genetic profiles. For example, TLR2-deficient mice develop purulent OM because of abundant infiltration of neutrophils related to the absence of goblet cell metaplasia/hyperplasia in the middle ear mucosa. 1 The genetic background interacts with other host and environmental factors to affect the phenotype of OM. Several animal model studies, as well as human studies, have solidified the link between OM phenotypes and genetics. 2 The branch of PM that addresses OM is referred to as ''precision OM,'' based on OM properties and genetic backgrounds, such as chronic OM, secretory OM, serous OM, mucous OM, and silent OM. A genetic predisposition or susceptibility to OM is a genetic characteristic feature that influences the possible phenotypic development. Genetic testing and analysis can identify individuals who are genetically predisposed or susceptible to certain OM phenotypes.
Precision Medicine in OM
Understanding of disease susceptibility factors (intrinsic and extrinsic), the characteristics of the pathogens, and how these potentially affect a patient provides a basis for precision medical care for OM. 3 Recent literature has highlighted the importance of distinguishing patterns of illness in acute OM to enable appropriate precision and individualized care. 4 Currently, these concepts apply primarily to clinical presentations, such as bilateral acute disease, to inform the use of antibiotics or surgical intervention. 5 However, the ability to use patient-specific genetic information to similarly influence treatment decisions has been much studied and published since the last symposium.
In OM, PM offers the potential to tailor a medical treatment to a subgroup of individuals who have similar genetic backgrounds, susceptibilities to pathogens, and responses to external stimuli. Preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and potential complications to those who will not.
Genetic Aspect of Inflammation
Inflammation is a hallmark of OM. Appropriate inflammation is essential for eradicating pathogens. However, excessive inflammation is clearly detrimental to the host.
Uncontrolled inflammation in the middle ear significantly contributes to the development and progression of OM. Thus, inflammation must be tightly regulated. However, little is known about how inflammation is regulated in the pathogenesis of OM.
A number of studies were carried out to investigate the role of proinflammatory mediators in OM, with in vitro and in vivo approaches. Zhang et al 6 found that blockade of macrophage migration inhibitory factor suppresses inflammation and improves the hearing level in an acute OM model. From a whole genome gene array analysis, Suzukawa et al 7 identified that heparin binding-epidermal growth factor is a key mediator of inflammation-induced mucosal proliferation in a mouse model of OM. Kurabi et al 8 found that mice lacking ASC, the inflammasome adaptor protein, exhibited impairment of IL-1b maturation, reduction in neutrophil recruitment, and bacteria clearance of nontypable Haemophilus influenzae (NTHi) in middle ear. Preciado et al 9 found that NTHi challenge in the mouse middle ear led to chronic epithelial mucosal metaplasia and that Cxcl2 was a key proinflammatory mediator.
Investigating the negative regulators of inflammation over the past years also brought novel insights into the tight regulation of inflammatory responses. Woo et al 10 found that IL-10/HMOX1 signaling played a critical role in protecting the cochlea from inflammation-mediated tissue damage through inhibition of MCP-1/CCL2 regulation. Wang et al 11 found that deubiquitinase cylindromatosis (CYLD) suppressed NTHi-induced expression of key proinflammatory chemokine IL-8 via MAP kinase phosphatase 1 (MKP-1)-dependent inhibition of ERK. In addition, Komatsu et al 12 identified phosphodiesterase 4B (PDE4B) as a key negative regulator for CYLD, and inhibition of PDE4B markedly suppressed bacteria-induced inflammation via upregulating CYLD expression by siRNA technology and Cyld-deficient mice. Taken together, all of these studies may lead to the development of new anti-inflammatory therapeutics by targeting key regulators of inflammation in OM.
Genes Relevant to Human OM
Genetic studies are one way to research the pathophysiology behind OM and eventually find new strategies for the therapy and prevention of OM. There are several strategies to conduct human genetic studies.
Heritability Studies
Heritability is the variance of phenotypic variation due to genotype and has been estimated on twin studies for OM. Hafrén et al estimated heritability from an OM-prone cohort of 590 families, consisting of 2436 subjects. The heritability estimates were 38.5% for recurrent acute OM, 22.1% for OM with effusion, and 47.8% for all OM. 13, 14 These results were somewhat lower than heritability estimates from twin studies.
Linkage Studies
The purpose of linkage studies is to find genomic loci associated to a phenotype. One or several families are genotyped, and with information about the affected status of the subject and genotype, the loci are calculated. Chen et al did a follow-up linkage study, fine-mapping chromosome 19 on their cohort of 139 families consisting of 607 study subjects. They replicated their previous finding of linkage to loci 19q (LOD BEST = 3.75). 15 Rye et al did a linkage study on a cohort of 468 subjects from 101 families. They found significant evidence of linkage to 10q26.3 (Z lr = 2.69, P = .0036) and borderline linkage to 10q22.3 (Z lr = 1.67, P = .05). They further fine mapped the region in a cohort of 256 affected cases and 575 controls with imputation data from a previous genome-wide association study (GWAS) that revealed 4 candidate genes: TCERG1L, PP2R2D, DOCK1, and ADAM12. Expression analysis and in silico analysis concluded that PPP2R2D, part of the TGFb pathway, is the most likely candidate gene underlying the linkage result. 16 Candidate Gene Association Studies. In candidate gene studies, the frequencies of a genetic marker is compared between affected study subjects and control subjects. The control subjects can be unrelated healthy controls (case-control study) or healthy siblings or other family members (family study). Sale et al conduced a candidate gene study on 15 genes with separate polymorphisms in 142 families with 618 subjects. Nominal genetic association was found for MUC5AC (rs2735733, P = .002, odds ratio [OR] = 0.646; rs7396030, P = .049, OR = 1.565; rs2075859, P = .041, OR = 0.744). Three other singlenucleotide polymorphisms (SNPs) at 3 separate genes showed a trend toward association: SCN1B (rs810008, P = .013), SFTPD (rs1051246, P = .039), and TLR4 (rs2770146, P = .038). 17 Rye at al studied the candidate gene SLC11A1 in 660 affected children from 531 families in a case/pseudo-control study. The best SNP association was in the genetic model at the rs2776631 (P = .025). Haplotype analysis revealed the 3_C_C_G haplotype (rs34448891_rs2276631_rs3731865_rs2695343) to be more common in the affected study subjects (P = .0008). Functional studies supported SLC11A1 as a novel candidate gene for OM. 18 A candidate gene study of 192 SNPs from 8 genes was conducted by MacArthur et al on 100 cases and 79 controls. Eight SNPs on 4 genes (TLR4, MUC5B, SMAD2, SMAD4) showed a trend toward association (P BEST_ADJUSTED = .625, rs10116253 on TLR4). 19 Nokso-Koivisto et al studied 21 SNPs as risk factors for upper respiratory tract infections, OM, and OM proneness in 653 children. An increased risk for OM proneness was associated with the CX3CR1 gene (Thr280Met, OR = 6.23, P = .038). Also white race combined with IL-1b (-511) wild type and IL-10 (-1082) non-wild type were associated with OM proneness. 20 A Greek cohort of 96 children was studied for 8 SNPs of 5 cytokine genes. IL-10 (-592, -819, and -1082) and TGFb (codon 10C.T) were associated with an increased number of acute OM episodes (P \ .001, P \ .001, P \ .001, and P = .002, respectively). IL-10 (-1082) and TGFb (codon 10C.T) were also associated to a later onset of AOM (P = .007 and P = .0039, respectively). 21 Gessner et al showed in 1032 study subjects from Alaska that those who were homozygous for the arctic variant of CPT1A (c.1436C.T) demonstrated a trend to more likely have OM (OR = 3.6, 95% confidence interval: 1.4-8.9). 22 Primary ciliary dyskinesia is a genetic disease inherited in an autosomal recessive manner. The prevalence of primary ciliary dyskinesia is estimated to be 1 in 20,000 live births. Congenital abnormality of the primary cilia results in situs inversus in 50% of patients. Decreased function of motile cilia causes chronic rhinosinusitis, OM with effusion, bronchiectasis, and infertility. 23 Hafrén et al did a candidate gene study with 53 SNPs on 624 study subjects with recurrent acute OM and/or chronic OM with effusion and 778 control subjects. The positive result for TLR4 (rs5030717, OR = 1.33, P = .003) was further investigated by a tagging SNP analysis, and 2 additional SNPs were identified (rs1329060 and rs1329057). There was an increased association among patients with a more severe phenotype: those with OM starting before the age of 6 months (OR = 2.42, P = .0005, for rs1329060) and those with repeated insertions of tympanostomy tubes (OR = 1.65, P = .00004 for rs1329060). The result was replicated in a Finnish OM cohort of 205 children (s1329060, OR = 1.32, P = .002; rs1329057, OR = 1.30, P = .003; rs5030717, OR = 1.34, P = .002). In 3 other cohorts (2 in the United States and 1 in United Kingdom), the 3 SNPs failed to show association with the risk for OM. 25 A TLR4 variant (Asp299Gly, rs4986790) is related to the colonization of Moraxella catarrhalis in the upper respiratory tract of children (43%) in comparison with the TLR4 wild type (9%) (RR = 4.91, P = .0001). 24, 25 The IL-10 rs1800896TC SNP and the IL-1a rs6746923A and AG SNPs were significantly more and less common, respectively, among children without a history of tympanic membrane perforation than among those who suffered from this complication. 26 Genome-wide Association Studies. Genome-wide association studies (GWASs) require no previous assumption on underlying genetic loci. They are used in the research of common, complex diseases. Hundreds of thousands to millions of SNPs are analyzed in cases and controls to find SNPs associated to the trait. Two GWASs have been published on OM.
The first was published by Australian colleagues Rye et al in 2012. They used the Illumina 660W-Quad to study 416 affected cases and 1075 controls. No marker showed genome-wide significance (P \ 10 -8
), but there was a trend toward association in the genes CAPN14 and GALNT14 on chromosome 2p23.1 and BPIFA3 and BPIFA1 on chromosome 20q11.21. The top results did not replicate in an independent cohort of 793 affected study subjects from 645 families, nor did they replicate in a North American cohort of 596 subjects and 370 affected. 27 The second GWAS study on OM was conducted on a North American cohort of 602 study subjects from 143 families, with 373 affected subjects. Allen et al used the Illumina Human CNV370-Duo. No SNP reached genomewide significance, but they conducted a replication study on 53 SNPs in an independent cohort of 1584 study subjects from 441 families. In an intergenic region on chromosome 2, the SNP rs10497394 replicated, thus giving a significant association to OM (P META-ANALYSIS = 1.52 3 10 -8 ). Three other SNPs on chromosomes 15 and 5 showed a trend toward association. 15 Allen et al 28 noted that diagnostic approaches such as human linkage studies and GWASs may provide new insights to OM research for the development of novel therapeutic strategies.
Sequencing. Sequencing is becoming more affordable these days and is mainly used to find rare variants in rare diseases. In recent years, there has also been an increasing number of studies on complex diseases. In 2015 SantosCortez et al published the first sequencing study on OM. 29 They did exome sequencing on 2 second cousins in a Filipino isolate populate where the prevalence of OM is almost 50%. They found a variant of A2ML1 (a-macroglobulin-like 1) as a new risk variant for OM. The result was replicated in 51 other subjects in the same isolate (LOD, 7.5). The variant is due to a duplication in the gene (p.Ser829Trpfs*9). A2ML1 is expressed in murine middle ear and is a rare, high genetic-risk variant for OM.
Genes Involved in Hearing Loss and OM in Animal Models
The mouse model is a useful tool to study and identify the genes relevant to OM. The advance in genetic studies through mutant mice is summarized in Table 1 .
30-61
Genes Whose Deficiency Results in OM
There are genes that are essential for the maintenance of the middle ear epithelial cell integrity and health. The deficiency of the following genes results in OM. (1) Tgif1-it functions through several routes as a negative regulator of the TGFb signaling pathway. Tgif1 mutant mice have significantly raised auditory thresholds due to a conductive deafness arising from OM. 37 (2) Phex-a mutation in the Phex gene is linked to predisposition to OM in mice. The mutation in the Phex gene primarily upregulates the expression level of the FGF23 gene in the middle ears. 39 There is a report where FGF23 mutant mice showed mixed hearing loss and middle ear malformation. 62 (3) Oxgr1-the Oxgr1 gene encodes oxoglutarate receptor 1. The ligand for Oxgr1 was reported to be involved in regulation of vascular endothelial growth factor, an important inducer of angiogenesis and vascular permeability. Oxgr1 deficiency demonstrated the presence of inflammatory cells, changes in the mucosal epithelium, and middle ear fluid in mice. 38 (4) Mcph1-the Mcph1-deficient mice had mild to moderate hearing impairment (around 70% penetrance). Other defects of Mcph1-deficient mice included small skull sizes, increased micronuclei in red blood cells, increased B cells, and ocular abnormalities. 36 (5) Df1-the Df1 gene is cytogenetic risk factor for schizophrenia and can cause hearing difficulties as well as a variety of other medical problems. 63 (6) Lmnamutant Lmna mice exhibited profound early-onset hearing deficits and abnormal positioning of the eustachian tube accompanied by OM. 40 (7) Spag6-mammalian spermassociated antigen 6 (Spag6) is required for normal flagella and cilia motility. The deficiency of this gene in humans causes OM due to accumulation of fluid and mucociliary abnormality. 32 
Genes Associated with Virulence in OM
(1) Hfq-in the chinchilla model of OM, the hfq mutant of 86-028NP exhibited impaired competitive fitness when compared with its wild-type progenitor but exhibited no apparent defect in virulence to elicit OM. 64 (2) HemRthis gene is involved in the uptake of iron and ironcontaining moieties, essential for Haemopilus. Variability of the HemR polymorphism may result in a reduced ability to acquire iron, rendering NTHi unable to survive in the middle ear. 65 (3) Fur-this gene is also essential for Haemopilus to grow in the middle ear. 66 (4) VapBC-1 VapXD ToxAVapA-deletions in vapBC-1, vapXD, and ToxAVapA significantly decreased the survival of NTHi in the chinchilla model of OM.
67,68
Signaling Pathways and Inflammatory Factors Involved in OM
(1) Asc-mice lacking the Asc gene showed a reduction in leukocyte recruitment and infiltration to the cavity, and their macrophages exhibited reduced phagocytosis of NTHi. 8 (2) Pai-1-plasminogen activator inhibitor (PAI-1) regulates inflammatory cell migration. PAI-1 knockout mice showed significant pathologic changes of tympanosclerosis. 30 (3) C5a-mice deficient in the C5a gene showed the reduced levels of IL-6, mKC, and MCP-1, in association with reduced inflammatory cell recruitment, mucosal inflammation, and bacterial clearance. 69 (4) Il17a-the function of interleukin 17A (IL-17A), a neutrophilinducing factor. Mice lacking the IL-17A gene were associated with abnormal recruitment and apoptosis of neutrophils. 70 
Mucin OM
Cxcl2 is identified as the most significant increased inflammatory mediator during the early acute phase of infection. Math1, a critical transcription factor, with proinflammatory cytokine tumor necrosis factor alpha (TNFa) and retinoid acid, promoted differentiation of normal mouse middle ear epithelium into mucus-producing cells via upregulation of mucins and trefoil factors. This results in pathologic mucous cell metaplasia and increased susceptibility of chronic OM. 34 GalNAc residue essential for binding of bacteria to respiratory epithelium is localized in mucinproducing epithelium and submucosal glands of normal rat eustachian tube. 71 Combination of certain NTHi and Streptococcus pneumoniae strains, but not all, worked synergistically to upregulate the gel-forming mucin transcripts. Mucins play a protective role in the epithelium but with their dysregulation can lead to mucus stasis. 72 Acrolein, a hazardous air pollutant in tobacco smoke, promoted inflammatory responses, mucin gene expression, and cell death in human middle ear epithelium culture. 73 Other air-suspended urban particles, both artificial and naturally occurring, induced COX-2 and MUC5AC expression in 
Isl1
A nonconservative tyrosine to cysteine (Y71C) missense mutation in the Islet1 gene, Isl1
Drsh.
C3HeB/FeJ background Predisposition carriers to OM.
44
Sh3pxd2b
Sh3pxd2b nee heterozygous mice All mice that had the Sh3pxd2bnee mutation went on to develop craniofacial dysmorphologies and subsequently OM, by as early as 11 days of age. 45 Factor B C57BL/6 mice Factor B deficiency decreases C3 activation during acute pneumococcal OM. Complement C3 activation and opsonophagocytosis of S pneumoniae were greatly attenuated in factor B-and factor B/C2-deficient mice. 46 
TNFA
TNFA deletion
The TNF and TNF receptor superfamilies mediate both inflammation and apoptosis during OM. TNFA is also required for appropriate regulation of caspase genes.
47
TLR9
Toll-like receptor 9 -/-mice on a C57BL/6 background DNA sensing via TLR9 plays a role in OM pathogenesis and recovery. 48 (continued)
human middle ear epithelium culture. 74 Injection of urban particle solution into rat middle ear induced mucosal changes and dysregulation of genes associated with inflammatory response and mucin production. 75 The impact of these environmental exposures on mucin regulation and mucosal changes conferred the development of OM.
Immune Tolerance of Middle Ear Mucosa
Clinically, the middle ear is considered an immuneprivileged area. 76 Homografts of the tympanic member usually survive for a long time without administration of any immunosuppressive drugs after surgery. 77 For this reason, the middle ear is tolerant to the invading upper respiratory commensals that reside and thrive, frequently causing OM. Consistent with this, immune-and inflammatory-related cytokines, such as TNFa and interferon gamma, 78, 79 are induced, which regulate the immunity of the middle ear mucosa against infectious agents. Programmed death ligand 1 (PD-L1), an inducible protein in the middle ear epithelial cells, is induced, which inhibits Abbreviations: CCL3, Chemokine (C-C motif) ligand 3; CCR2, C-C chemokine receptor type 2; HB-EGF, heparin-binding-epidermal growth factor; KO, knockout; MCP-1,monocyte chemoattractant protein-1; OM, otitis media; Y71C, a nonconservative tyrosine to cysteine.
middle ear immunity when PD-L1 binds to its receptor, programmed death 1 (PD-1), on the surface of mucosal lymphocytes. [80] [81] [82] This way, the PD pathway is formed in the middle ear mucosa to suppress the immunity of the middle ear, making a regional immunotolerance at this specific tissue while the entire immune system is normal.
PD-L1 negatively regulates the activity of effector T lymphocytes, including intraepithelial lymphocytes, in the mucosa, 80, 83 reducing the production of IL-2, which is a major cytokine to expand T cells. T cells participate in the innate and adaptive immunity. Due to the negative effects of PD-L1 on the T-cell activity, the innate and adaptive immune systems are both suppressed, and invading microorganisms survive and thrive in the middle ear. This is a unique phenotype of OM characterized by the activation of the PD pathway. In this particular phenotype of OM, the PD pathway may serve as a novel target for the treatment of OM.
New Intervention for OM
Nonconventional approaches to treatment were examined in an OM animal model. The noninvasive transcutaneous immunization to induce protective immune responses against NTHi-induced OM was conducted in the chinchilla model. The vaccine formula, utilizing a new chimeric immunogen, targeted 2 important bacterial outer membrane proteins and effectively removed mucosal surface bacteria and mucosal biofilm in the middle ear. The increase of activated T cells and the release of host defense peptide contributed to a rapid disease resolution. 84 Antimicrobial activity of photodynamic therapy with porfimer sodium (Photofrin) was assessed against clinical isolates of Mcat. The treatment demonstrated significant reduction in planktonic bacteria and viable bacteria in the biofilm structure. 85 Various drug delivery methods were attempted to improved efficacy of OM treatment. OTO-201, a sustainedrelease formula of ciprofloxacin administered via intratympanic injection, was proved to be more effective and convenient in OM treatment. 86 Levofloxacin thermosensitive gel allowed on-site delivery and prolonged the release of antibiotics in the middle ear space. This characteristic provides effective treatment of suppurative OM without recurrence. 87 In summary, there have been more animal models available for genetic studies regarding OM in recent years and more genes in animal models and human genetic linkage studies relevant to the pathogenesis of OM. In general, these studies are evolving, and the relationship between these genes and human OM remains to be clarified in the years to come.
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